Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

The pharmaceutical companies behind Ozempic, Wegovy and other weight-loss meds push to prevent compounding pharmacies from ...

Major drugmakers are filing lawsuits against the HHS and HRSA to try to resuscitate plans to issue hospitals rebates instead ...

The Health Resources and Services Administration has “invoked the nuclear option of removal from not only the 340B program ...

The FDA updated GLP-1 drug labels to warn of the risk of patients breathing food into their lungs while under anesthesia for ...

When a medication is in shortage, which Eli Lilly’s Zepbound has been for most of the year, the Food and Drug Administration (FDA) allows pharmacies to make compounded, or altered versions of ...

Lilly and Pfizer ... Resources and Services Administration (HRSA), an agency of the U.S. Department of Health and Human ...

Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) approved EBGLYSS™ (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for the treatment of adults and ...

are the first related to copycat tirzepatide since the U.S. Food and Drug Administration took the drug off its list of medicines in short supply earlier this month. Lilly said these lawsuits ...

But Eli Lilly's supply woes began to ease earlier this year, and the Food and Drug Administration removed tirzepatide, the ...

are the first related to copycat tirzepatide filed since the U.S. Food and Drug Administration took the drug off its list of medicines in short supply earlier this month. Lilly said these lawsuits ...